Incyte Company Profile (NASDAQ:INCY)

About Incyte (NASDAQ:INCY)

Incyte logoIncyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:INCY
  • CUSIP: 45337C10
  • Web:
  • Market Cap: $27.52 billion
  • Outstanding Shares: 204,774,000
Average Prices:
  • 50 Day Moving Avg: $127.03
  • 200 Day Moving Avg: $120.78
  • 52 Week Range: $71.75 - $153.15
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 292.13
  • P/E Growth: -3.64
Sales & Book Value:
  • Annual Revenue: $1.23 billion
  • Price / Sales: 22.37
  • Book Value: $4.72 per share
  • Price / Book: 28.47
  • EBIDTA: $35.53 million
  • Net Margins: 14.71%
  • Return on Equity: 50.38%
  • Return on Assets: 10.58%
  • Debt-to-Equity Ratio: 1.74%
  • Current Ratio: 3.69%
  • Quick Ratio: 3.67%
  • Average Volume: 2.72 million shs.
  • Beta: 0.78
  • Short Ratio: 2.12

Frequently Asked Questions for Incyte (NASDAQ:INCY)

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) released its quarterly earnings results on Thursday, May, 4th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.97) by $0.01. The firm had revenue of $384.08 million for the quarter, compared to the consensus estimate of $359.19 million. Incyte had a return on equity of 50.38% and a net margin of 14.71%. The company's revenue for the quarter was up 45.8% on a year-over-year basis. During the same quarter last year, the business posted $0.12 EPS. View Incyte's Earnings History.

Where is Incyte's stock going? Where will Incyte's stock price be in 2017?

22 analysts have issued twelve-month price objectives for Incyte's shares. Their predictions range from $98.00 to $185.00. On average, they expect Incyte's share price to reach $141.11 in the next twelve months. View Analyst Ratings for Incyte.

What are analysts saying about Incyte stock?

Here are some recent quotes from research analysts about Incyte stock:

  • 1. According to Zacks Investment Research, "Incyte’s first-quarter results were encouraging as the company reported a narrower-than-expected loss and surpassed revenue expectations. The growth in Jakafi sales is driven by patient demand and should boost revenues. While most of the demand is due to a larger established patient base in myelofibrosis, polycythemia vera is also expected to be a major long-term driver of Jakafi growth. This is owing to the larger potential patient population and the possibility for longer duration of treatment. The company exited the first quarter with approximately 10,000 patients being treated with Jakafi. However, Incyte’s dependence on a single product, Jakafi, for growth is concerning. Moreover, the FDA has issued a CRL to new drug application (NDA) for baricitinib asking for additional information. The delay in approval is disappointing. Moreover, loss estimates for 2017 have widened significantly following the first-quarter results." (5/23/2017)
  • 2. Cowen and Company analysts commented, "Incyte reported Q1 financials and provided a pipeline update." (5/5/2017)
  • 3. Instinet analysts commented, "Incyte has been incrementally expanding the opportunity for its JAK franchise in oncology and autoimmune. We anticipate near-term upside from novel JAK combos, formulations, and applications in oncology and autoimmune disease. These under-recognized programs represent $25/sh of our target price and, in our view, offer lower-risk opportunities vs. epacadostat." (3/1/2017)
  • 4. Jefferies Group LLC analysts commented, "Solid, unsurprising Valentine's Day 4Q report, with good Jakafi metrics and increasing depth from the maturing pipeline building towards broad, more diversified long-term growth opportunities. We continue to see upside potential in 2017 supported by continued Jakafi execution, IDO data/progress, and bari launch enthusiasm, with scarcity value likely continuing to drive M&A speculation. Adjust tgt to $140 from $136." (2/15/2017)

Are investors shorting Incyte?

Incyte saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 5,351,232 shares, an increase of 25.4% from the March 31st total of 4,265,752 shares. Based on an average daily volume of 1,940,983 shares, the days-to-cover ratio is presently 2.8 days. Currently, 2.6% of the shares of the company are short sold.

Who are some of Incyte's key competitors?

Who owns Incyte stock?

Incyte's stock is owned by many different of institutional and retail investors. Top institutional investors include BAKER BROS. ADVISORS LP (16.80%), Vanguard Group Inc. (8.14%), State Street Corp (3.70%), BB Biotech AG (1.84%), FMR LLC (1.57%) and Brown Capital Management LLC (0.99%). Company insiders that own Incyte stock include Barry P Flannelly, David W Gryska, Eric H Siegel, James M Daly, Jean Jacques Bienaime, Julian Baker, Paul A Friedman, Paula J Swain, Reid M Huber, Richard S Levy, Steven H Stein and Yao Wenqing. View Institutional Ownership Trends for Incyte.

Who sold Incyte stock? Who is selling Incyte stock?

Incyte's stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Nicholas Investment Partners LP, Marshall Wace LLP, Brown Capital Management LLC, Point72 Asset Management L.P., BB Biotech AG, Cibc World Markets Corp and Tekla Capital Management LLC. Company insiders that have sold Incyte stock in the last year include Barry P Flannelly, David W Gryska, Eric H Siegel, Paul A Friedman, Paula J Swain, Reid M Huber and Steven H Stein. View Insider Buying and Selling for Incyte.

Who bought Incyte stock? Who is buying Incyte stock?

Incyte's stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., Victory Capital Management Inc., Geode Capital Management LLC, Morgan Stanley, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P. and UBS Asset Management Americas Inc.. Company insiders that have bought Incyte stock in the last two years include Jean Jacques Bienaime and Julian Baker. View Insider Buying and Selling for Incyte.

How do I buy Incyte stock?

Shares of Incyte can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Incyte stock cost?

One share of Incyte stock can currently be purchased for approximately $134.38.

Analyst Ratings

Consensus Ratings for Incyte (NASDAQ:INCY) (?)
Ratings Breakdown: 4 Hold Ratings, 18 Buy Ratings
Consensus Rating:Buy (Score: 2.82)
Consensus Price Target: $141.11 (5.01% upside)

Analysts' Ratings History for Incyte (NASDAQ:INCY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/18/2017Oppenheimer Holdings Inc.Set Price TargetHold$125.00HighView Rating Details
5/18/2017JPMorgan Chase & Co.Set Price TargetBuy$149.00MediumView Rating Details
5/19/2017Morgan StanleyReiterated RatingOverweight$142.00MediumView Rating Details
5/18/2017Jefferies Group LLCReiterated RatingBuy$148.00LowView Rating Details
5/15/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
5/15/2017BMO Capital MarketsBoost Price TargetOutperform$144.00 -> $146.00N/AView Rating Details
5/12/2017CIBCReiterated RatingMarket Perform -> Market Perform$125.00LowView Rating Details
5/9/2017Credit Suisse Group AGSet Price TargetOutperform$167.00 -> $152.00LowView Rating Details
4/19/2017SunTrust Banks, Inc.Lower Price TargetBuy$160.00 -> $145.00LowView Rating Details
4/19/2017Barclays PLCLower Price TargetOverweight$185.00 -> $180.00LowView Rating Details
4/18/2017Goldman Sachs Group IncLower Price TargetBuy$149.00 -> $136.00LowView Rating Details
4/17/2017Raymond James Financial, Inc.Reiterated RatingHoldHighView Rating Details
4/17/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Neutral$124.00MediumView Rating Details
4/10/2017GabelliInitiated CoverageBuy -> Buy$185.00MediumView Rating Details
4/4/2017Royal Bank of CanadaBoost Price TargetOutperform$138.00 -> $157.00LowView Rating Details
3/21/2017William BlairInitiated CoverageOutperformLowView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$148.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
1/18/2017JMP SecuritiesReiterated RatingOutperform$130.00N/AView Rating Details
11/20/2016Leerink SwannReiterated RatingOutperform$101.00 -> $115.00N/AView Rating Details
9/26/2016ArgusBoost Price TargetBuy$92.00 -> $98.00N/AView Rating Details
6/6/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
1/31/2016Bank of America CorpReiterated RatingBuy$145.00 -> $87.00N/AView Rating Details
11/19/2015UBS Group AGReiterated RatingBuy$130.00N/AView Rating Details
(Data available from 5/28/2015 forward)


Earnings History for Incyte (NASDAQ:INCY)
Earnings by Quarter for Incyte (NASDAQ:INCY)
Earnings History by Quarter for Incyte (NASDAQ:INCY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.97)($0.96)$359.19 million$384.08 millionViewListenView Earnings Details
2/14/2017Q416$0.14$0.05$324.90 million$326.00 millionViewListenView Earnings Details
11/1/2016Q316($0.04)$0.11$260.98 million$269.50 millionViewN/AView Earnings Details
8/9/2016Q216($0.02)$0.18$236.91 million$208.00 millionViewN/AView Earnings Details
5/9/2016Q116$0.29$0.12$266.38 million$263.00 millionViewN/AView Earnings Details
2/11/2016Q415$0.09$0.29$223.54 million$243.88 millionViewListenView Earnings Details
11/3/2015Q315($0.41)($0.22)$179.30 million$187.70 millionViewN/AView Earnings Details
8/4/2015Q215($0.11)($0.04)$153.27 million$162.98 millionViewListenView Earnings Details
4/30/2015Q115($0.06)($0.11)$155.21 million$159.30 millionViewListenView Earnings Details
2/12/2015Q414($0.14)($0.22)$138.37 million$106.00 millionViewListenView Earnings Details
10/30/2014Q3$0.02$0.33$149.92 million$198.15 millionViewListenView Earnings Details
7/31/2014Q214($0.09)($0.22)$140.72 million$99.58 millionViewListenView Earnings Details
5/1/2014Q114($0.19)($0.21)$97.70 million$89.80 millionViewListenView Earnings Details
2/12/2014Q413($0.10)($0.15)$98.04 million$97.10 millionViewListenView Earnings Details
10/31/2013Q313($0.13)($0.14)$81.40 million$85.10 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.08$0.05$114.34 million$101.70 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.12)$68.16 million$71.10 millionViewListenView Earnings Details
2/14/2013Q4 2012($0.02)$0.14$92.03 million$113.80 millionViewListenView Earnings Details
11/1/2012Q312($0.21)($0.17)$60.61 million$60.50 millionViewN/AView Earnings Details
8/2/2012($0.02)$0.03ViewN/AView Earnings Details
4/26/2012($0.48)($0.36)ViewN/AView Earnings Details
2/15/2012($0.40)($0.44)ViewN/AView Earnings Details
10/27/2011($0.43)($0.42)ViewN/AView Earnings Details
7/28/2011($0.36)($0.41)ViewN/AView Earnings Details
5/3/2011($0.32)($0.21)ViewN/AView Earnings Details
2/10/2011$0.19$0.26ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Incyte (NASDAQ:INCY)
2017 EPS Consensus Estimate: ($0.44)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.01)($0.82)($0.93)
Q2 20175($0.08)$0.61$0.28
Q3 20174($0.08)$0.32$0.12
Q4 20175($0.06)$0.27$0.09
(Data provided by Zacks Investment Research)


Dividend History for Incyte (NASDAQ:INCY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Incyte (NASDAQ:INCY)
Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 92.62%
Insider Trades by Quarter for Incyte (NASDAQ:INCY)
Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)
Insider Trades by Quarter for Incyte (NASDAQ:INCY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Jean Jacques BienaimeDirectorBuy500$115.00$57,500.00View SEC Filing  
5/8/2017Reid M HuberEVPSell8,577$119.21$1,022,464.17View SEC Filing  
5/1/2017Eric H SiegelEVPSell1,820$124.73$227,008.60View SEC Filing  
4/28/2017Jean Jacques BienaimeDirectorBuy500$124.26$62,130.00View SEC Filing  
4/13/2017Jean Jacques BienaimeDirectorBuy1,000$139.66$139,660.00View SEC Filing  
4/10/2017David W GryskaInsiderSell41,528$138.00$5,730,864.00View SEC Filing  
4/10/2017Eric H SiegelEVPSell4,043$140.18$566,747.74View SEC Filing  
4/7/2017Jean Jacques BienaimeDirectorBuy1,000$139.48$139,480.00View SEC Filing  
4/7/2017Steven H SteinEVPSell32,000$137.88$4,412,160.00View SEC Filing  
3/17/2017Paul A FriedmanDirectorSell50,000$148.72$7,436,000.00View SEC Filing  
1/9/2017Reid M. HuberEVPSell11,739$113.55$1,332,963.45View SEC Filing  
11/9/2016Reid M. HuberEVPSell2,715$109.95$298,514.25View SEC Filing  
10/20/2016Paula J SwainEVPSell10,000$90.00$900,000.00View SEC Filing  
10/7/2016Barry P FlannellyEVPSell24,204$97.00$2,347,788.00View SEC Filing  
9/23/2016Paula J SwainEVPSell20,000$90.00$1,800,000.00View SEC Filing  
8/2/2016Reid M. HuberEVPSell10,000$87.96$879,600.00View SEC Filing  
7/29/2016Paula J SwainEVPSell60,000$90.00$5,400,000.00View SEC Filing  
3/17/2016Julian BakerDirectorBuy800,000$63.98$51,184,000.00View SEC Filing  
2/25/2016Julian BakerDirectorBuy64,290$70.79$4,551,089.10View SEC Filing  
2/16/2016Julian BakerDirectorBuy887,165$69.87$61,986,218.55View SEC Filing  
2/12/2016Julian BakerDirectorBuy2,251,427$63.53$143,033,157.31View SEC Filing  
1/15/2016Paula J. SwainEVPSell13,531$76.96$1,041,345.76View SEC Filing  
1/6/2016Richard S. LevyEVPSell3,937$101.86$401,022.82View SEC Filing  
12/7/2015Richard S. LevyEVPSell3,937$106.18$418,030.66View SEC Filing  
11/18/2015Paul A. FriedmanDirectorSell225,000$113.83$25,611,750.00View SEC Filing  
11/10/2015Eric H. SiegelEVPSell2,222$104.86$232,998.92View SEC Filing  
11/6/2015Richard S. LevyEVPSell3,936$116.51$458,583.36View SEC Filing  
11/3/2015Yao WenqingEVPSell5,786$124.78$721,977.08View SEC Filing  
10/13/2015Eric H. SiegelEVPSell2,222$101.49$225,510.78View SEC Filing  
10/6/2015Richard S. LevyEVPSell3,937$122.29$481,455.73View SEC Filing  
9/21/2015Reid M. HuberEVPSell10,000$124.29$1,242,900.00View SEC Filing  
9/16/2015Eric H. SiegelEVPSell2,222$130.69$290,393.18View SEC Filing  
9/11/2015Richard S LevyEVPSell4,301$130.00$559,130.00View SEC Filing  
9/8/2015Richard S. LevyEVPSell3,937$118.90$468,109.30View SEC Filing  
8/13/2015Eric H SiegelEVPSell2,222$107.69$239,287.18View SEC Filing  
7/15/2015Richard S LevyEVPSell70,217$120.00$8,426,040.00View SEC Filing  
7/14/2015Eric H SiegelEVPSell2,222$113.61$252,441.42View SEC Filing  
7/6/2015Richard S LevyEVPSell3,937$107.00$421,259.00View SEC Filing  
6/23/2015James M DalyEVPSell11,691$108.24$1,265,433.84View SEC Filing  
6/19/2015Richard S LevyEVPSell20,000$108.13$2,162,600.00View SEC Filing  
6/12/2015Eric H SiegelEVPSell2,223$105.31$234,104.13View SEC Filing  
6/8/2015Richard S LevyEVPSell3,937$107.58$423,542.46View SEC Filing  
5/27/2015Paul A FriedmanDirectorSell196,751$107.23$21,097,609.73View SEC Filing  
5/22/2015Paul A FriedmanDirectorSell102,243$108.22$11,064,737.46View SEC Filing  
5/14/2015Eric H SiegelEVPSell2,222$104.99$233,287.78View SEC Filing  
4/23/2015James M DalyEVPSell36,941$107.67$3,977,437.47View SEC Filing  
4/17/2015Yao WenqingEVPSell7,150$102.04$729,586.00View SEC Filing  
4/14/2015Eric H SiegelEVPSell2,222$98.72$219,355.84View SEC Filing  
4/13/2015Yao WenqingEVPSell23,000$95.18$2,189,140.00View SEC Filing  
4/7/2015Yao WenqingEVPSell20,031$90.13$1,805,394.03View SEC Filing  
3/30/2015Laurent ChardonnetVPSell113,776$93.64$10,653,984.64View SEC Filing  
3/30/2015Reid M HuberEVPSell34,263$93.66$3,209,072.58View SEC Filing  
3/12/2015Barry A ArikoDirectorSell80,000$89.27$7,141,600.00View SEC Filing  
3/12/2015Eric H SiegelEVPSell2,222$89.72$199,357.84View SEC Filing  
2/25/2015Eric H SiegelEVPSell13,333$85.00$1,133,305.00View SEC Filing  
2/24/2015James M DalyEVPSell11,112$82.19$913,295.28View SEC Filing  
2/17/2015Paula J SwainEVPSell17,500$76.90$1,345,750.00View SEC Filing  
1/26/2015Eric H SiegelEVPSell13,542$79.85$1,081,328.70View SEC Filing  
1/23/2015James M DalyEVPSell11,109$77.68$862,947.12View SEC Filing  
1/20/2015Paula J SwainEVPSell17,500$74.17$1,297,975.00View SEC Filing  
1/16/2015Richard S LevyEVPSell12,000$73.07$876,840.00View SEC Filing  
1/8/2015Eric H SiegelEVPSell15,626$75.00$1,171,950.00View SEC Filing  
1/6/2015Richard S LevyEVPSell25,000$71.84$1,796,000.00View SEC Filing  
1/5/2015Paula J SwainEVPSell17,500$73.90$1,293,250.00View SEC Filing  
12/23/2014James M DalyEVPSell11,113$74.43$827,140.59View SEC Filing  
12/2/2014Schutter Richard U DeChairmanSell50,000$74.89$3,744,500.00View SEC Filing  
11/6/2014Paul A FriedmanDirectorSell185,653$67.87$12,600,269.11View SEC Filing  
10/23/2014James M DalyEVPSell11,111$53.49$594,327.39View SEC Filing  
9/23/2014James M DalyEVPSell11,111$47.65$529,439.15View SEC Filing  
9/16/2014Richard S LevyEVPSell8,000$47.58$380,640.00View SEC Filing  
8/18/2014Richard S LevyEVPSell8,000$51.97$415,760.00View SEC Filing  
7/23/2014James M DalyEVPSell11,111$48.54$539,327.94View SEC Filing  
7/16/2014Richard S LevyEVPSell8,000$48.15$385,200.00View SEC Filing  
6/23/2014James M DalyEVPSell11,111$56.03$622,549.33View SEC Filing  
6/16/2014Richard S LevyEVPSell8,000$53.88$431,040.00View SEC Filing  
6/5/2014David C HastingsCFOSell200,000$52.73$10,546,000.00View SEC Filing  
5/23/2014James M DalyEVPSell11,111$48.48$538,661.28View SEC Filing  
5/16/2014Richard LevyEVPSell8,000$50.68$405,440.00View SEC Filing  
5/2/2014Laurent ChardonnetVPSell34,000$51.55$1,752,700.00View SEC Filing  
4/23/2014James DalyEVPSell30,555$47.71$1,457,779.05View SEC Filing  
2/20/2014Paul FriedmanDirectorSell33,354$63.51$2,118,312.54View SEC Filing  
2/19/2014Paul FriedmanDirectorSell771,182$65.65$50,628,098.30View SEC Filing  
2/19/2014Schutter Richard DeChairmanSell50,000$65.53$3,276,500.00View SEC Filing  
2/18/2014David HastingsCFOSell275,000$65.86$18,111,500.00View SEC Filing  
9/10/2013Paul A FriedmanCEOSell376,789$37.32$14,061,765.48View SEC Filing  
9/9/2013Laurent ChardonnetVPSell44,834$37.31$1,672,756.54View SEC Filing  
9/6/2013David C HastingsCFOSell100,000$35.16$3,516,000.00View SEC Filing  
9/6/2013Richard S LevyEVPSell25,000$35.28$882,000.00View SEC Filing  
9/5/2013Paula J SwainEVPSell94,444$35.06$3,311,206.64View SEC Filing  
8/19/2013Roy WhitfieldDirectorSell50,000$26.70$1,335,000.00View SEC Filing  
5/17/2013Roy A WhitfieldDirectorSell40,000$23.08$923,200.00View SEC Filing  
5/13/2013Richard S LevyEVPSell55,699$22.30$1,242,087.70View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Incyte (NASDAQ:INCY)
Latest Headlines for Incyte (NASDAQ:INCY)
DateHeadline logoIncyte Co. (INCY) Stock Rating Upgraded by TheStreet - May 27 at 7:32 AM logoIncyte Co. (INCY) Expected to Post Quarterly Sales of $316.31 Million - May 26 at 4:02 PM logo Analysts Anticipate Incyte Co. (INCY) to Announce $0.01 Earnings Per Share - May 24 at 2:14 PM logoBlog Coverage: Amgen Announces New Data from the FOURIER Trial - May 23 at 11:17 AM logoIncyte Co. (INCY) Raised to Hold at Zacks Investment Research - May 23 at 9:26 AM logoIncyte's (INCY) Overweight Rating Reaffirmed at Morgan Stanley - May 20 at 7:40 AM logoJPMorgan Chase & Co. Reiterates "$149.00" Price Target for Incyte Co. (INCY) - May 19 at 7:16 PM logoIncyte Co. (INCY) PT Set at $125.00 by Oppenheimer Holdings Inc. - May 19 at 5:54 PM logoBiotech Breakout Ahead? Incyte Rising On Success With Merk, Bristol-Myers - May 19 at 5:37 PM logoBristol-Incyte Match Beats Dow's Merck In Combination Trials - May 19 at 5:37 PM logoIncyte: Why Wait For ASCO…Cancer Drug Data Incites Investors - May 19 at 10:27 AM logoA $25 billion biotech's stock is popping on its promising cancer data - May 19 at 10:27 AM logoIncyte's (INCY) Buy Rating Reaffirmed at Jefferies Group LLC - May 18 at 11:40 AM logoInitial data from Phase 1/2 study of Incyte's epacadostat + Opdivo to be presented at ASCO; shares ahead 8% premarket - May 18 at 9:26 AM logoJean Jacques Bienaime Acquires 500 Shares of Incyte Co. (INCY) Stock - May 17 at 8:34 PM logoIncyte Shares Jump After 'IDO' Cancer Immunotherapy Combo Data Revealed - - May 17 at 5:53 PM logoMerck, Incyte immunotherapy combination effective in lung cancer study - Reuters - May 17 at 5:53 PM logoOppenheimer Holdings Comments on Incyte Co.'s Q2 2017 Earnings (INCY) - May 15 at 7:46 AM logoToni’s Kitchen’s Toni Julian | Women of Influence 2017 - May 12 at 6:35 PM logoIncyte Co. (INCY) Now Covered by Analysts at CIBC - May 12 at 6:30 PM logoIncyte Co. (INCY) Given Average Rating of "Buy" by Brokerages - May 12 at 12:50 PM logoIncyte Co. (INCY) Now Covered by Oppenheimer Holdings Inc. - May 12 at 9:53 AM logoCalithera Biosciences' (CALA) CEO Susan Molineaux on Q1 2017 Results - Earnings Call Transcript - May 10 at 1:21 PM logoReid M. Huber Sells 8,577 Shares of Incyte Co. (INCY) Stock - May 9 at 7:20 PM logoCalithera Biosciences Reports First Quarter 2017 Financial Results and Recent Highlights - May 9 at 5:40 PM logoIncyte Co. (INCY) Issues Quarterly Earnings Results - May 8 at 11:53 PM logoIncyte Co. (INCY) Posts Earnings Results - May 8 at 10:26 PM logoIncyte Co. Expected to Post FY2020 Earnings of $4.15 Per Share (INCY) - May 8 at 12:26 PM logoIncyte Co. Expected to Post FY2019 Earnings of $1.61 Per Share (INCY) - May 8 at 12:12 PM logoSunTrust Banks Brokers Decrease Earnings Estimates for Incyte Co. (INCY) - May 8 at 10:44 AM logoLeerink Swann Analysts Lower Earnings Estimates for Incyte Co. (INCY) - May 8 at 10:44 AM logoTheStreet Downgrades Incyte Co. (INCY) to D+ - May 8 at 12:28 AM logoIncyte Co. (INCY) Given "Buy" Rating at Cowen and Company - May 7 at 10:04 AM logoMerus: A Buy On Lucrative Incyte Partnership And 2017 Catalysts - May 6 at 9:49 AM logoIncyte Co. (INCY) Rating Reiterated by BMO Capital Markets - May 5 at 8:56 PM logoIncyte (INCY) Q1 2017 Results - Earnings Call Transcript - May 4 at 11:08 PM logoEdited Transcript of INCY earnings conference call or presentation 4-May-17 2:00pm GMT - May 4 at 11:08 PM logoIncyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs - May 4 at 8:04 AM logoInvestor Network: Incyte Corporation to Host Earnings Call - May 4 at 8:04 AM logoIncyte reports 1Q loss - May 4 at 7:30 AM logo$353.56 Million in Sales Expected for Incyte Co. (INCY) This Quarter - May 3 at 2:50 PM logoJean Jacques Bienaime Purchases 500 Shares of Incyte Co. (INCY) Stock - May 2 at 10:22 PM logoIncyte Co. (INCY) EVP Sells $227,008.60 in Stock - May 2 at 9:56 PM logoState Treasurer State Of Michigan Buys Procter & Gamble Co, Walt Disney Co, ... - May 2 at 10:30 AM logo5 Toxic Stocks to Dispose of or Play Short for Profit - May 2 at 10:29 AM logoIncyte Co. (INCY) Expected to Announce Earnings of -$0.96 Per Share - May 1 at 5:50 PM logoIncyte Corporation (INCY) Leads 11 Activist Investor Filings - May 1 at 10:49 AM logoSomewhat Favorable News Coverage Likely to Affect Incyte (INCY) Stock Price - April 30 at 12:23 AM logoIncyte Co. (INCY) Short Interest Up 25.4% in April - April 29 at 7:20 AM logoShould You Get Rid of Incyte Corporation (INCY) Now? - April 26 at 7:25 PM



Incyte (INCY) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by Staff